SMARCA4 and adenocarcinoma: In addition to pro‐NEtD genetic alterations, there are also genetic alterations that conversely inhibit NEtD and maintain an adenocarcinoma lineage state, such as TMPRSS2–ERG fusion inhibiting NEtD in prostate cancer186 and SMARCA4 loss reverse NEtD in SCLC.62